CENCOR reported fiscal 2026 adjusted diluted EPS of $17.97, up 12%. For fiscal 2027, it guides to adjusted diluted EPS of $19.40 to $19.75, consolidated revenue growth of 3 percent to 5 percent, and operating income growth of 4% to 6%.
COR · Cencora, Inc.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Key stats
- Close
- $341.25
- Open
- $345.03
- Day range
- $337.11–347.73
- 52-week closing range
- $252.74–374.75
- Average volume, 30 days
- 1.4M
- Short interest
- 3.2M · 1.7% of shares · 2.6 days
- Short volume, last session
- 55%
- Last earnings
- Nov 4, 2026
- Latest filing
- 10-Q · Aug 5
- Price history
- Jan 2020 to Nov 2026
Up next
Latest documents
Cencora recently completed an operating-model restructuring and will begin reporting in a new structure in the first quarter of fiscal 2027: Pharmaceutical Distribution and Services, Specialty Pharmaceutical and Provider Services, and Other.
Cencora reported fiscal 2026 revenue of $337.4 billion, up 5.0 percent, and adjusted diluted EPS of $17.97. It expects fiscal 2027 adjusted diluted EPS of $19.40 to $19.75 and increased its quarterly dividend to $0.66 per share.
Cencora agreed to acquire American Oncology Network for an enterprise value of $2.4 billion, comprising $2.3 billion at closing and contingent value rights of up to $100 million. It updated fiscal year 2026 adjusted diluted EPS expectations to at least $17.90.
Cencora appointed Robert E. Sanchez as an independent director, effective October 1, 2026, increasing its board from ten to eleven members; he is Executive Chair of Ryder System, Inc.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q4 FY26 earnings call · Nov 4, 2026TL;DR. Fiscal 2026 delivered 5.0% revenue growth, 14.0% adjusted operating income growth and 12.3% adjusted diluted EPS growth; fiscal 2027 guidance calls for 3%–5% revenue growth, 4%–6% operating income growth and 8%–10% adjusted EPS growth. Specialty is forecast to deliver 18%–21% operating income growth in fiscal 2027, while Cencora generated $3.8 billion of free cash flow, increased its dividend 10% and plans another $1.25 billion of repurchases. Risks include an approximately 5 percentage-point operating-income headwind from Businesses and Other, distribution-segment headwinds, higher interest expense and elevated operating costs.
- − Businesses and Other are expected to reduce fiscal 2027 consolidated operating income growth by approximately 5 percentage points, largely because of the assumed MWI-Covetrus merger. new
- − Pharmaceutical Distribution and Services operating income growth is expected to be 2%–4%, including a customer volume-shift impact and an approximately $20 million foreign-exchange headwind. new
- − Fiscal 2027 net interest expense is expected to be $490 million–$510 million, reflecting debt raised for the OneOncology transaction. new
- − Fourth-quarter U.S. Healthcare Solutions revenue growth was partly offset by $2.8 billion of manufacturer list-price reductions and lower sales to a large mail-order customer. new
- − Portfolio actions may create near-term financial headwinds despite concentrating resources on areas aligned with the pharmaceutical-centric strategy. new
- − Fiscal 2026 adjusted operating expenses increased 23.7%, largely because of the OneOncology and RCA acquisitions, partly offsetting gross-profit growth. new
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Days inventory on hand | 26.6 | Three months ended June 30, 2026 filing | — |
| Days payable outstanding | 59.7 | Three months ended June 30, 2026 filing | — |
| Days sales outstanding | 27.1 | Three months ended June 30, 2026 filing | — |
| U.S. Healthcare Solutions' operating income margin | 1.29% | the three months ended June 30, 2026 filing | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Distribution — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
COR
this stock
Cencora, Inc.
|
$65.12B | +1.0% | +9.3% | 25.3 | 1.7% |
|
MCK
Mckesson Corp
|
$122.63B | +29.5% | +3.1% | 27.4 | 1.7% |
|
CAH
Cardinal Health Inc
|
$62.95B | +32.5% | +14.2% | — | 3.3% |
|
HSIC
Henry Schein Inc
|
$9.37B | +12.2% | +5.9% | 23.2 | 8.5% |
|
EBOSY
EBOS Group Limited
|
$2.37B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 4, 2026
- This year
- 32
Cencora reported fiscal 2026 revenue of $337.4 billion, up 5.0 percent, and adjusted diluted EPS of $17.97. It expects fiscal 2027 adjusted diluted EPS of $19.40 to $19.75 and increased its quarterly dividend to $0.66 per share.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| COR | -2.3% | +0.8% | +28.9% | +3.2% | +1.0% |
| SPY | -5.5% | -6.3% | -5.6% | -5.3% | +5.0% |
| vs SPY | +3.1% | +7.1% | +34.6% | +8.4% | -3.9% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.